Cadila launches Cadilose for constipation and hepatic encephalopathy

AbbVie wins FDA nod for DECNUPAZ in rare blood cancer

BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

OBESITAS 2026 concludes with focus on India’s rising obesity burden

The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research

The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results

MetaVia’s DA-1726 shows breakthrough weight loss in Phase 1 trial

Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit

HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer

ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium